You are conducting a study comparing the efficacy of two different statin medications. Two groups are placed on different statin medications, statin A and statin B. Baseline LDL levels are drawn for each group and are subsequently measured every 3 months for 1 year. Average baseline LDL levels for each group were identical. The group receiving statin A exhibited an 11 mg/dL greater reduction in LDL in comparison to the statin B group. Your statistical analysis reports a p-value of 0.052. Which of the following best describes the meaning of this p-value?

There is a 5.2% chance of observing a difference in reduction of LDL of 11 mg/dL or greater even if the two medications have identical effects

There is a 95% chance that the difference in reduction of LDL observed reflects a real difference between the two groups

Though A is more effective than B, there is a 5% chance the difference in reduction of LDL between the two groups is due to chance

If 100 permutations of this experiment were conducted, 5 of them would show similar results to those described above

This is a statistically significant result

A 57-year-old man presents to his oncologist to discuss management of small cell lung cancer. The patient is a lifelong smoker and was diagnosed with cancer 1 week ago. The patient states that the cancer was his fault for smoking and that there is "no hope now." He seems disinterested in discussing the treatment options and making a plan for treatment and followup. The patient says "he does not want any treatment" for his condition. Which of the following is the most appropriate response from the physician?

"It must be very challenging having received this diagnosis. I want to work with you to create a plan."

"You seem upset at the news of this diagnosis. I want you to go home and discuss this with your loved ones and come back when you feel ready to make a plan together for your care."

"It must be tough having received this diagnosis; however, new cancer therapies show increased efficacy and excellent outcomes."

"We are going to need to treat your lung cancer. I am here to help you throughout the process."

"I respect your decision and we will not administer any treatment. Let me know if I can help in any way."

A research team is working on a new assay meant to increase the sensitivity of testing in cervical cancer. Current sensitivity is listed at 77%. If this research team's latest work culminates in the following results (listed in the table), has the sensitivity improved, and, if so, then by what percentage? Research team's latest results: | | Patients with cervical cancer | Patients without cervical cancer | |--------------------------|-------------------------------|----------------------------------| | Test is Positive (+) | 47 | 4 | | Test is Negative (-) | 9 | 44 |

Yes, the research team has seen an improvement in sensitivity of almost 7% according to the new results listed.

No, the research team has seen a decrease in sensitivity according to the new results listed.

No, the research team has not seen any improvement in sensitivity according to the new results listed.

Yes, the research team has seen an improvement in sensitivity of more than 10% according to the new results listed.

Yes, the research team has seen an improvement in sensitivity of less than 2% according to new results listed; this improvement is negligible and should be improved upon for significant contribution to the field.

A pharmaceutical company reports a new antihypertensive drug reduces cardiovascular events with an NNT of 50 over 5 years based on a trial of 10,000 patients. An independent analysis reveals the benefit was driven entirely by a subgroup with resistant hypertension (20% of participants, NNT=15), while the remaining 80% showed no benefit over standard therapy (NNT approaching infinity). Evaluate the ethical and regulatory implications of reporting the overall NNT.

The overall NNT is misleading; approval should be restricted to resistant hypertension population where benefit is demonstrated

Conduct a new trial in the general hypertensive population to validate efficacy before broader approval

The subgroup analysis represents data dredging; only the overall NNT should be used for clinical decisions

The overall NNT of 50 is statistically valid and appropriate for regulatory approval and marketing

Report both overall and subgroup NNTs; allow clinicians to determine appropriate use based on patient characteristics

NNT in prevention vs treatment for USMLE Step 2 CK: High-Yield Biostatistics Lessons

NNT/NNH - The Core Formulae

Number Needed to Treat (NNT): The average number of patients who need to be treated to prevent one additional bad outcome. The ideal NNT is 1.
- Formula: $NNT = 1 / ARR$
- ARR (Absolute Risk Reduction): The actual difference in risk between control and treatment groups.
- Calculation: $ARR = |CER - EER|$
  - CER: Control Event Rate (risk in placebo/standard care group).
  - EER: Experimental Event Rate (risk in treatment group).
Number Needed to Harm (NNH): The number of individuals that need to be treated for one person to experience an adverse event.
- Formula: $NNH = 1 / ARI$ (Absolute Risk Increase).

⭐ NNT is the reciprocal of the Absolute Risk Reduction (ARR), not the Relative Risk Reduction (RRR).

📌 NNT is always rounded UP to the next whole number (you can't treat half a person).

NNT in Action - Prevention vs. Treatment

The application of Number Needed to Treat (NNT) differs significantly between preventing a disease in a healthy population and treating a condition in an affected one. The key determinant is the baseline risk, or the Absolute Risk (AR), in the control group.

Characteristic	Prevention Setting	Treatment Setting
Baseline Risk	Low (healthy population)	High (diseased population)
NNT Value	Generally higher	Generally lower
Time Horizon	Long (years to decades)	Short (days to months)
Intervention	Prophylactic (e.g., statins)	Therapeutic (e.g., antibiotics)
Effect (ARR)	Smaller Absolute Risk Reduction	Larger Absolute Risk Reduction

⭐ A high NNT for a common condition (e.g., hypertension) in a prevention trial can have a greater public health impact than a low NNT for a rare disease because a small benefit is applied to a massive population.

Clinical Context - Reading the Numbers

Clinical Significance: A low NNT is desirable, but is it clinically meaningful? Treating 100 people to prevent one minor headache is different from preventing one death.
Interpreting NNT/NNH:
- 📌 LoNNT is Lovely (Low NNT is good).
- 📌 HiNNH is Horrible (High NNH is good).
Holistic View: NNT is just one piece of the puzzle. Always weigh it against:
- NNH: How many patients are harmed for every one that benefits?
- Side Effects: Severity and frequency of adverse events.
- Cost: Is the intervention affordable for the patient and healthcare system?
- Patient Values: What does the patient prefer?
- Disease Severity: NNT for a terminal vs. self-limiting disease carries different weight.

Benefit-risk and variability across clinical scenarios

⭐ Always consider the NNT alongside the NNH; a treatment with a good NNT might be rejected if the NNH for a serious side effect is too low.

High‑Yield Points - ⚡ Biggest Takeaways

NNT = 1/ARR; it's the number of patients to treat to prevent one bad outcome. Lower is better.

NNH = 1/AR; it's the number of patients to treat for one to be harmed. Higher is better.

NNT for prevention is generally higher than for treatment.

This is because the baseline risk in a healthy population is much lower.

The most effective interventions have a very low NNT and a very high NNH.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play